Trial Profile
Demonstration of Pharmacodynamic Equivalence of Enoxaparin Rovi (100-mg Subcutaneous Injection) to Clexane® (100-mg Subcutaneous Injection) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Deep vein thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Pharmacokinetics
- Sponsors Rovi
- 08 Dec 2017 New trial record